Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA N6-methyladenine (6mA) modification regulators are a class of proteins responsible for the dynamic addition (writers), removal (erasers), and recognition (readers) of the 6mA epigenetic mark on deoxyadenosine. While 6mA is a well-established epigenetic modification in prokaryotes, its role in eukaryotes has recently gained attention, particularly regarding its influence on gene expression and chromatin structure in human cancers (Xiao et al., 2018). Specific proteins such as Protein Phosphatase 1 Regulatory Subunit 3A (PPP1R3A) and Autophagy Related 3 (ATG3) have been identified in bioinformatic signatures as key regulators or correlates of 6mA dynamics in malignancies like colorectal cancer, where they are associated with tumor progression and patient prognosis (Li et al., 2021). These regulators often possess dual roles; for example, ATG3 is a critical E2-like enzyme in the autophagy pathway, while PPP1R3A regulates glycogen synthesis, suggesting that 6mA-mediated epigenetic control may be integrated with fundamental cellular metabolic and homeostatic processes (Xie et al., 2018). Targeting these regulators offers a novel therapeutic avenue for modulating oncogenic signaling, though the multi-functional nature of proteins like ATG3 and PPP1R3A presents significant challenges for achieving therapeutic specificity without disrupting vital cellular functions.
Modulation of DNA N6-methyladenine levels to regulate the expression of oncogenes or tumor suppressors through changes in chromatin accessibility and transcriptional activity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA N6-methyladenine modification regulators (6mA regulators).